v3.10.0.1
Condensed Consolidated Interim Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended 9 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Sales $ 930,257 $ 260,960 $ 1,978,675 $ 570,327
Cost of Sales 450,304 88,357 1,087,540 177,482
Gross Margin 479,953 172,603 891,135 392,845
Operating expenses        
Sales and marketing 515,439 432,260 1,485,423 1,313,077
Research and development 779,283 546,350 2,135,075 1,947,659
General and administrative 1,022,024 783,784 2,932,980 2,916,917
Share-based compensation expense (Note 11) 191,634 271,001 1,226,374 1,284,257
Amortization (Note 4) 69,314 76,985 209,682 246,920
Depreciation (Note 7) 15,969 21,234 50,190 69,606
Total operating expenses 2,593,663 2,131,614 8,039,724 7,778,436
Other (income) expenses        
Foreign exchange (47,709) (11,485) (116,715) 102,671
Accretion expense (Note 8) 316,642 216,302 2,421,060 290,375
Fair value adjustment (Note 8) 0 0 (337,923) 0
Gain on mark to market revaluation (Note 10) 0 0 (2,048,697) 0
Other expense 1,520 416,931 61,652 657,999
Total other expenses (income) 270,453 621,748 (20,623) 1,051,045
Net loss and comprehensive loss for the period $ (2,384,163) $ (2,580,759) $ (7,127,966) $ (8,436,636)
Loss per share - basic and diluted $ (0.91) $ (3.80) $ (3.14) $ (12.74)
Weighted average number of shares outstanding – basic 2,611,538 678,631 2,267,906 662,237
Weighted average number of shares outstanding – diluted 2,611,538 678,631 2,267,906 662,237

Source